PCR Journal Club

Long-term evidence comparing PCI and CABG for unprotected left main coronary disease has been limited and sometimes conflicting. The 10-year results from the NOBLE trial now provide important clarity on all-cause mortality outcomes with both revascularisation strategies.

The RENOVATE-COMPLEX-PCI 5-year outcomes confirm the long-term durability of benefits seen with intracoronary imaging over angiography guided PCI in complex lesions.

Women have long been underrepresented in TAVR trials. This article explores the DEDICATE trial’s sex-specific outcomes after TAVI and SAVR, revealing differences in early stroke risk, procedural challenges, and one-year survival in men and women with aortic stenosis.

Catheter-based left atrial appendage closure (LAAC) is widely used as an alternative to oral anticoagulation in atrial fibrillation. But how does it compare with best medical therapy in patients at high risk of both stroke and bleeding? The CLOSURE-AF trial provides new data to inform this...

The ROLLING STONE registry compares intravascular lithotripsy (IVL) and atherectomy (rotational and orbital) for treating heavily calcified coronary arteries, assessing real-world safety and effectiveness in percutaneous coronary interventions (PCI).

This study provides the longest available follow-up for first-generation bioresorbable vascular scaffolds and fails to demonstrate any late clinical advantage after complete scaffold resorption.

The 3-year follow-up of the REC-CAGEFREE I trial demonstrated that a DCB-based strategy with rescue stenting was associated with a significantly higher rate of DOCE compared with contemporary DES implantation in patients with de novo, non-complex coronary artery disease.

The TICO1 and T-PASS2 trials evaluated abbreviated DAPT followed by ticagrelor monotherapy compared to DAPT in patients with ACS undergoing PCI. Both trials demonstrated the safety and efficacy of abbreviated DAPT however, the optimal timing of aspirin discontinuation remains uncertain. This post hoc analysis compares the...

The 6-year results of the Evolut Low Risk trial confirm the absence of significant differences in the composite primary endpoint between TAVR and surgery, but introduce an important nuance: the first signal of increased valve reintervention in the TAVR arm within this trial.

Patients with severe symptomatic aortic stenosis and small annuli—most often women—face higher risks of elevated gradients, patient–prosthesis mismatch and early valve failure after TAVI, with added challenges for future coronary access and redo procedures, particularly in younger populations.

While previous studies have mainly compared supra-annular balloon- and...